文献速递肿瘤 PET/CT

全身[68Ga]Ga-PSMA-11 PET/CT相比常规[68Ga]Ga-PSMA-11 PET/CT提高生化复发前列腺癌患者的检出率

Total-body [68 Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-08-14

纳入200例生化复发前列腺癌患者,100例接受全身[68Ga]Ga-PSMA-11 PET/CT(早期及利尿延迟显像),另100例接受常规[68Ga]Ga-PSMA-11 PET/CT(早期及利尿延迟显像)。全身PET/CT检出率显著高于常规PET/CT(91.0% vs. 74.0%,P=0.003),且对Gleason评分≤8或PSA≤2 ng/ml患者检出效率更好,利尿延迟全身显像优势更明显。

要点

  • 全身[68Ga]Ga-PSMA-11 PET/CT检出率91.0%,常规PET/CT为74.0%,差异有统计学意义(P=0.003)。
  • 全身PET/CT对Gleason评分≤8或PSA≤2 ng/ml患者的检出效率更好。
  • 利尿延迟全身[68Ga]Ga-PSMA-11 PET/CT的优势更明显。

核心结论

  • 全身[68Ga]Ga-PSMA-11 PET/CT相比常规[68Ga]Ga-PSMA-11 PET/CT可显著提高生化复发前列腺癌患者的检出率(91.0% vs. 74.0%,P=0.003)。

研究设计与样本

  • 纳入200例临床病理特征相似的生化复发前列腺癌患者,100例接受早期及利尿延迟全身[68Ga]Ga-PSMA-11 PET/CT,另100例接受早期及利尿延迟常规[68Ga]Ga-PSMA-11 PET/CT。
  • 采用卡方检验和分层分析比较全身与常规[68Ga]Ga-PSMA-11 PET/CT的检出率,并基于主观评分和客观参数比较图像质量。
  • 主观评分从背景噪声和病灶突出度按5分制进行,客观参数评估肝脏和臀大肌的SUVmax、SUVmean、SUV标准差(SD)及信噪比(SNR),并测量复发灶SUVmax。

主要发现

  • 全身[68Ga]Ga-PSMA-11 PET/CT的肝脏SD显著低于常规[68Ga]Ga-PSMA-11 PET/CT,SNR显著高于常规[68Ga]Ga-PSMA-11 PET/CT,主观评价显著优于常规[68Ga]Ga-PSMA-11 PET/CT。
  • 全身[68Ga]Ga-PSMA-11 PET/CT对前列腺癌生化复发的检出率显著高于常规[68Ga]Ga-PSMA-11 PET/CT(91.0% vs. 74.0%,P=0.003)。
  • 全身[68Ga]Ga-PSMA-11 PET/CT对Gleason评分≤8或PSA≤2 ng/ml患者的检出效率更好。
  • 利尿延迟全身[68Ga]Ga-PSMA-11 PET/CT的优势更明显。

临床怎么用

  • 原文结论为全身[68Ga]Ga-PSMA-11 PET/CT相比常规[68Ga]Ga-PSMA-11 PET/CT可显著提高生化复发前列腺癌患者的检出率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to assess whether total-body [68 Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer. METHODS: Two hundred biochemical recurrent prostate cancer patients with similar clinicopathological characteristics were included, of whom 100 patients underwent early total-body [68 Ga]Ga-PSMA-11 PET/CT and diuretic-delayed total-body [68 Ga]Ga-PSMA-11 PET/CT, and the other 100 patients received early conventional [68 Ga]Ga-PSMA-11 PET/CT and diuretic-delayed conventional [68 Ga]Ga-PSMA-11 PET/CT. The detection rates of total-body [68 Ga]Ga-PSMA-11 PET/CT and conventional [68 Ga]Ga-PSMA-11 PET/CT were compared using a chi-square test and stratified analysis. The image quality of total-body [68 Ga]Ga-PSMA PET/CT and conventional [68 Ga]Ga-PSMA-11 PET/CT was compared based on subjective scoring and objective parameters. Subjective scoring was conducted from background noise and lesion prominence using a 5-point scale. Objective parameters were evaluated by SUVmax, SUVmean, the standard deviation (SD) of SUV, and the signal-to-noise ratio (SNR) of liver and gluteus maximus. The SUVmax of the recurrent lesions was also measured. RESULTS: The liver SD of the total-body [68 Ga]Ga-PSMA-11 PET/CT was significantly lower than that of conventional [68 Ga]Ga-PSMA-11 PET/CT, the SNR was significantly higher than that of conventional [68 Ga]Ga-PSMA-11 PET/CT, and the subjective evaluation was significantly better than that of conventional [68 Ga]Ga-PSMA-11 PET/CT. The detection rate of total-body [68 Ga]Ga-PSMA PET/CT for biochemical recurrence of prostate cancer was significantly higher than that of conventional [68 Ga]Ga-PSMA-11 PET/CT (91.0% vs. 74.0%, P = 0.003). Total-body [68 Ga]Ga-PSMA-11 PET/CT had better detection efficiency for patients with a Gleason score ≤ 8 or PSA ≤ 2 ng/ml. The advantages of diuretic-delayed total-body [68 Ga]Ga-PSMA-11 PET/CT were more obvious. CONCLUSION: Total-body [68 Ga]Ga-PSMA-11 PET/CT could significantly improve the detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang Y, Chen Z, Zhu Y, et al. Total-body [68 Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 37578502. doi:10.1007/s00259-023-06355-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。